$CADL

Candel Therapeutics (Nasdaq: CADL) said its Compensation Committee granted Mark Sims, Chief Commercial Officer, inducement stock options for 285,000 shares at a $10.03 exercise price on July 6, 2026. Options vest 25% after one year, then 75% in monthly installments, subject to continued service. Plan adopted Dec. 24, 2025.

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001841387 false 0001841387 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23,

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 cadl-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“ Agreement ”) is made between Candel Therapeutics, Inc., a Delaware corporation (the “ Company ”), and Charles Schoch. (the “ Executive ”) and is made effective as of June 12,

Candel Therapeutics, Inc. announced its strategy for advancing oncology programs, with CEO Paul Peter Tak presenting at the Stifel 2026 Virtual Targeted Oncology Forum. The company is focusing on its clinical pipeline, specifically in prostate cancer, non-small cell lung cancer (NSCLC), and recurrent glioma. This presentation offers an early look at Candel's strategy and research developments in the oncology sector, highlighting their commitment to patient-driven innovation and regulatory standards.

Candel Therapeutics, Inc. has released new extended follow-up data from its phase 3 trial for CAN-2409 in localized prostate cancer. The results, presented at the #AUA26 meeting, provide further insight into the efficacy and durability of the investigational immunotherapy. This comes alongside other recent company recognition, such as the CEO emphasizing patient engagement and the Chief Regulatory Officer being named among RAPSorg 50 for 50.

Candel Therapeutics (NASDAQ: CADL) reported positive extended follow-up results from its pivotal Phase 3 trial of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk localized prostate cancer. The immunotherapy, combined with standard radiotherapy, demonstrated a 39% improvement in prostate cancer-specific disease-free survival in the overall population and 41% in the intermediate-risk subgroup, with significant hazard ratios. The treatment was well-tolerated, and Candel plans to submit a Biologics License Application (BLA) in Q4 2026, positioning CAN-2409 as a potential new therapy in over 20 years.

Candel Therapeutics announced extended follow-up data from its pivotal Phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer. The data showed a statistically significant 39% improvement in prostate cancer–specific disease-free survival and favorable trends in other clinical endpoints, particularly in intermediate-risk patients. These findings reinforce the potential of aglatimagene to reduce tumor recurrence and represent a significant advancement for patients with localized prostate cancer, where standard-of-care radiation therapy has seen little change in over 20 years.

Candel Therapeutics reported a net loss of $(8.9)M and diluted EPS of $(0.14) for Q1 2026, a significant downturn from the previous year's positive figures. Despite the financial loss, the company highlighted several business advancements, including positive Phase 3 prostate trial data, progress in NSCLC programs, and ongoing clinical momentum for other therapies. Candel Therapeutics is also preparing for a potential prostate launch and scaling up manufacturing.

Candel Therapeutics, a clinical-stage biopharmaceutical company, announced it has granted inducement stock options to five new employees. These options, totaling 70,000 shares of common stock at an exercise price of $4.90 per share, were made under the company's 2025 Inducement Plan. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are designed to attract and retain talent.

Candel Therapeutics announced a public offering of 18.35 million common shares at $5.45 per share, aiming to raise $100 million to fund the advancement of aglatimagene besadenovec (CAN-2409) for prostate cancer and non-small cell lung cancer, as well as for general corporate purposes. The offering led to an 11.76% decrease in CADL stock price to $5.25. The company plans to use the proceeds for launch readiness, medical affairs, and pre-commercialization activities for aglatimagene, and for ongoing development costs of its phase 3 trial in NSCLC.